Indication: Endometrial Cancer
Title: SIENDO: Maintenance with selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer
SIENDO is a Phase 3 study evaluating once weekly selinexor as a maintenance therapy versus placebo in patients with endometrial cancer after first- or second-line chemotherapy.
This trial is for selinexor.
|Early Stage||Mid Stage||Late Stage||Commercial|